Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 10 Show results per page	View Search Criteria \| Help With Results

First Published: 10/8/2008


1.		Phase I/II Study of ABT-888 in Combination With Radiotherapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Approved-not yet active				18 and over				NCI, Pharmaceutical / Industry				NABTT-0801 0801, ABBOTT-M10-190, NCT00770471


2.		A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Approved-not yet active				18 and over				Pharmaceutical / Industry				M10-440 NCT00804908

Last Modified: 10/10/2008 First Published: 10/31/2007


3.		Phase I Study of ABT-888 in Combination With Topotecan Hydrochloride in Patients With Advanced or Refractory Solid Tumors, Lymphoma, or Chronic Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				NCI-07-C-0203 P7241, 7981, NCT00553189

Last Modified: 11/28/2007 First Published: 9/20/2007


4.		Phase I Study of ABT-888, Carboplatin, and Paclitaxel in Patients With Advanced Solid Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				PCI-07-015 07-015, 7967, NCT00535119


5.		A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				M06-862 NCT00526617

Last Modified: 5/21/2008 First Published: 12/19/2007


6.		Phase I Study of ABT-888 and Topotecan Hydrochloride With or Without Carboplatin in Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				JHOC-J0783 J0783, 7968, NCT00588991

Last Modified: 7/30/2008 First Published: 12/17/2007


7.		Phase I Study of Irinotecan Hydrochloride and ABT-888 in Patients With Metastatic or Unresectable Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				Over 18				NCI				WSU-2007-014 2007-014, 7977, NCT00576654


8.		A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				M10-128 NCT00649207

Last Modified: 8/22/2008 First Published: 8/21/2008


9.		Phase I Study of ABT-888 and Cyclophosphamide in Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				CINJ-050803 050803, 7998, NCT00740805

Last Modified: 1/7/2009 First Published: 12/16/2008


10.		Phase I Study of ABT-888 and Metronomic Cyclophosphamide in Patients With Refractory Solid Tumors or Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				NCI-09-C-0048 09-C-0048, 8275, P8437, NCT00810966

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute